Supplementary Data 1 from A Phase II Trial of the CD40 Agonist Sotigalimab (APX005M) in Combination with Nivolumab in Subjects with Metastatic Melanoma with Disease Progression on Anti-PD-1
Key Points
Key points are not available for this paper at this time.
Abstract
Representativeness of Study Participants
KI fragen
Like
Bookmark
Share
KI fragen
Like
Bookmark
Share
Supplementary Data 1 from A Phase II Trial of the CD40 Agonist Sotigalimab (APX005M) in Combination with Nivolumab in Subjects with Metastatic Melanoma with Disease Progression on Anti-PD-1 | Synapse